CANVASC WEBINAR SERIES

2022 ANCA Workshop Update
June 22nd, 2022 7:30-8:30pm EST

After attending this event, participants will be better able to:

Identify the key points presented at the EULAR conference and incorporate these into clinical practice;
Utilize new evidence for the management of EGPA, GPA and MPA;
Consider various perspectives on current controversies in any vasculitis

Christian Pagnoux, MD, MSc, MPH
Associate Professor, University of Toronto
Sinai Hospital
Toronto, ON Canada

Mats Junek, MD, MSc
Rheumatology Fellow, McMaster University
St. Joseph's Healthcare
Hamilton, ON Canada

Natasha Dehghan, MD, FRCPC
Clinical Assistant Professor, University of BC
Mary Pack Arthritis Centre
Vancouver, BC Canada

ANCA Vasculitis, Diagnostics, and Management: A personal story of more than 35 years of experience with ANCA determinations.
September 27th, 2022 7:30-8:30pm EST

After attending this event, participants will be better able to:

Understand the development and identification of ANCA as a biomarker (pathogenesis info);
Apply clinical strategies for the use of ANCA in the diagnosis and follow-up in ANCA Vasculitis;
Appreciate and consider new advances for the role of ANCA in the management of vasculitis

Moderated by:

Speaker:

Jan Willem Cohen Tervaert, MD, PhD
Professor, Director, Division Rheumatology
University of Alberta
Edmonton, AB Canada
Emeritus Professor of Medicine and Immunology
Maastricht University, The Netherlands

Lillian Barra, MD, MPH, FRCPC
Associate Professor
Schulich School of Medicine and Dentistry
University of Western Ontario
London, ON Canada

EULAR Recommendations for the Management of ANCA-Associated Vasculitis: 2022 Update
October 17th, 2022 12:30-1:30pm EST

After attending this event, participants will be better able to:

Identify the key points presented at the EULAR conference and incorporate these into clinical practice;
Utilize new evidence for the management of EGPA, GPA and MPA;
Consider various perspectives on current controversies in any vasculitis

Bernhard Hellmich, MD, Professor of Medicine
University of Tübingen
Medius Kliniken, Department of Internal Medicine,
Rheumatology & Immunology
Kirchheim unter Teck, Germany

Lillian Barra, MD, MPH, FRCPC
Associate Professor
Schulich School of Medicine and Dentistry
University of Western Ontario
London, ON Canada

Update from the FVSG (French Vasculitis Study Group)
French Presentation: February 3rd, 2023 12:00-1:00pm EST |
English Presentation: February 14th, 2023 12:00-1:00pm EST

After attending this event, participants will be better able to;

Evaluate the duration and regimens for remission-maintenance in ANCA-associated vasculitis;
Consider the use of rituximab in Eosinophilic granulomatosis with polyangiitis (EGPA).

Benjamin Terrier, MD, PhD
Internal Medicine
National Referral Center for Autoimmune Diseases
Hôpital Cochin, Paris, France

*English Presentation

*French Presentation

Vasculitis Updates from ACR and the ASN

Thursday December 14, 2023, 7:00-8:00pm EST

After attending this event, participants will be better able to:

Identify the key points presented at the ACR and the ASN and incorporate these into clinical practice;
Utilize new evidence for the management of vasculitis;
Consider various perspectives on current updates in vasculitis.

Bryce Barr, MD

Associate Professor

University of Manitoba

Winnipeg, MB

Stephanie Garner, MD, MSc, FRCPC

Clinical Assistant Professor

University of Calgary

Calgary, AB

Lillian Barra, MD, MPH, FRCPC

Associate Professor

Schulich School of Medicine and Dentistry

London, ON

Recommendations for the Management of EGPA

Thursday March 14, 2024 1:00-2:00pm EST

After attending this event, participants will be better able to:

Differentiate between EGPA and other disorders; how to develop the diagnostic work up.
Identify the main patient characteristics that guide treatment in EGPA (FFS, other clinical manifestations)
Consider the main treatment approaches for severe vs non severe EGPA and for newly diagnosed vs relapsing disease.
Identify the differences between the European and US EGPA guidelines.

Christian Pagnoux, MD, MSc, MPH

Associate Professor, Founder and Vice-Director of CanVasc
Mount Sinai Hospital
Vasculitis Clinic, Division of Rheumatology
Department of Medicine, University of Toronto

Augusto Vaglio, MD, PhD

Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Italy
Nephrology and Dialysis Unit, Meyer Children’s Hospital, Florence, Italy

Tools for Improving the Diagnosis of GCA

Monday May 27, 2024

After attending this event, participants will be better able to:

Review the role for temporal artery biopsy, ultrasound, and MRI in Giant cell arteritis.
Discuss challenges in diagnosing Giant cell arteritis.
Summarize new and emerging approaches for diagnosing Giant cell arteritis.

Jean-Paul Makhzoum, MD MSc

FRCPC FACP

Associate Professor

University of Montréal

Mats Junek MD MSc PhD(c) FRCPC
Rheumatologist
McMaster University

Michael Seidman, MD PhD
Assistant Professor
University of Toronto

Update from the American College of Rheumatology Convergence 2024
December 3, 2024 7:00-8:00pm EST

After attending this event, participants will be better able to:

Identify the key points in vasculitis presented at the ACR and discuss how to incorporate these into clinical practice (or not [yet])
Utilize new evidence for the management of vasculitis
Consider various perspectives on current updates in vasculitis

Christian Pagnoux, MD, MSc, MPH
Associate Professor
University of Toronto
Toronto, ON

Hugues Allard-Chamard, MD, PhD, FRCPC
Assistant Professor
Université de Sherbrooke

Marie Clements-Baker, MD
Associate Professor
Queen’s University
Kingston, ON

Reducing Corticosteroid Exposure in ANCA Vasculitis: EGPA

Tuesday March 25, 2025 7:00-8:00 PM EST

Part 1 of the 2025 CanVasc webinar series.

After attending this event, participants will be better able to:

Appreciate the role of glucocorticosteroids in EGPA and the toxicity related to steroids
Consider the evidence of anti-IL5 biologics as steroid-sparing therapies in EGPA
Relate steroid sparing to eosinophil suppression
Compare the effects of steroids vs biologics on Vasculitic vs non-Vasculitic components of EGPA

Parameswaran Nair

MD, PhD, FRCP, FRCPC, FCAHS

Professor of Medicine

McMaster University

Nader A. Khalidi, MD, FRCPC

Professor of Medicine

McMaster University

Update on Pediatric Vasculitis

Thursday October 9, 2025 7:00-8:00 PM EST

Part 2 of the 2025 CanVasc webinar series.

After attending this event, participants will be better able to:

Identify the differences between adult and pediatric vasculitides;
Support the transition of care from pediatrics to adult care;
Identify the challenges of studying and treating pediatric vasculitis and the potential solutions to overcome barriers.

Kimberly Morishita
MD, FRCPC, MHSc

Clinical Associate Professor, University of British Columbia

Marinka Twilt, MD, MSCE, PhD

Professor, University of Calgary

IgG4-Related Disease

Wednesday, December 10th, 2025 7:00-8:00 PM EST

Part 3 of the 2025 CanVasc webinar series.

After attending this event, participants will be better able to:

Understand the role of glucocorticoids in the treatment of IgG4-RD.
Appreciate the impact that B-cell depletion has had on the field.
Gain insight into how to follow patients for recurrent disease activity.
Consider other novel potential treatments.

John H. Stone, M.D., M.P.H.

Professor of Medicine
Harvard Medical School
The Edward A. Fox Chair in Medicine
Massachusetts General Hospital
Executive Chairman
The IgG4ward! Foundation